Cargando…

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

BACKGROUND: Mutant peptides presented by MHC (major histocompatibility complex) Class II in cancer are important targets for cancer immunotherapy. Both animal studies and clinical trials in cancer patients showed that CD4 T cells specific to tumor-derived mutant peptides are essential for the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Weijing, Zhou, Dapeng, Wu, Weibo, Tan, Wen Ling, Wang, Jiaqian, Zhou, Caicun, Lou, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090856/
https://www.ncbi.nlm.nih.gov/pubmed/30075702
http://dx.doi.org/10.1186/s12864-018-4958-5